Multicentric randomized pilot research on “low dose immunotherapy” conducted by specialists at a private cancer hospital in Bengaluru has yielded promising results in patients with head and neck cancer.
“This open-labeled prospective study provides an affordable cancer treatment option in the management of head and neck cancers,” said experts at the HCG Cancer Center where the study was conducted.
The multicentric study compares the effectiveness of neoadjuvant therapy combining low-dose immunotherapy Nivolumab and the TPF regimen (docetaxel, cisplatin, and 5-fluorouracil) to neoadjuvant chemotherapy (NACT) with the TPF regimen alone, according to Satheesh C.T., Consultant – Medical and Hemato Oncology – and director of Clinical Trials at the hospital.
“It has a potential role in improving the quality of life and longevity of patients with locally advanced carcinoma of the buccal mucosa,” the doctor added.
Twelve patients in the 54-76 age range were evaluated as part of the pilot research. “In the pilot study, standard NACT is combined with low-dose Nivolumab immunotherapy, administering 40 mg every two weeks, as opposed to the full dose of 3 mg per kg of body weight,” Dr. Satheesh added.
Cancer’s toll
Head and neck cancers are a major global health concern, accounting for 4.5% of all cancer cases globally and carrying a 4.6% fatality rate. The burden is especially severe in Asia, particularly in India, where they account for about 35% of all cancer cases among those aged 40 to 60. Every year, around two lakh instances of head and neck cancer are identified in India.